Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

47 results about "Pulmonary vessels" patented technology

The vessels of the pulmonary circulation are the pulmonary arteries and the pulmonary veins. A separate system known as the bronchial circulation supplies oxygenated blood to the tissue of the larger airways of the lung.

Implantable recyclable pulmonary vessel pressure sensor and use method thereof

An implantable recyclable pulmonary vessel pressure sensor is characterized in that a group of nickel-titanium hyperelastic alloying metal wires is connected in an end-to-end manner to form a self-expanding oval support, a pressure sensor is arranged on any one of the nickel-titanium hyperelastic alloying metal wires of the self-expanding oval support, and a tail hook is arranged at one end of the self-expanding oval support. The self-expanding oval support with the pressure sensor reaches a lesion site through a press holding type delivery catheter, and after fixation is released, the pressure sensor is capable of sensing pressure signals of monitoring sites continuously; when a reader is implanted on the chest skin, real-time pressure signals and measured values can be monitored and displayed through a pressure sensing system in the reader, the reader can be connected to a pressure analyzer through a needle hole connection jack at the bottom end of the reader, the pressure signals can be printed in real time through the pressure analyzer, all pressure records in the reader are stored, and the self-expanding oval support can be recycled at any time through the tail hook. The implantable recyclable pulmonary vessel pressure sensor and a use method thereof have the advantages of simplicity in operation, small test result errors, no pain on patients, low cost, accurate results, wide application and continuous replacement of existing materials.
Owner:陈绍良

Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders

ActiveUS20160331816A1Improved right heart functionDecreased pulmonary vessel wall thicknessPowder deliveryPeptide/protein ingredientsDiseaseUveitis
Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration.
Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1

Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimental induced ocular disorders

Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration.Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1

Application of aminoadamantane mononitrate compound in preparation of drugs for preventing and treating diseases

The invention provides application of an aminoadamantane mononitrate compound in preparation of drugs for preventing and treating diseases such as glaucoma, vascular dementia, subarachnoid hemorrhage and pulmonary arterial hypertension. Discovered by experiments, the aminoadamantane mononitrate compound can be combined with an NMDA receptor and release nitric oxide (NO), excitatory toxicity of nerve cells induced by glutamic acid can be lowered, the compound plays a role in dilating cerebral blood vessels, cerebral blood flow can be improved, but peripheral blood pressure is not lowered; retinal ganglion cell injury induced by high intraocular pressure can be reduced, and the intraocular pressure is lowered through releasing the NO; in a vascular dementia model, the cerebral blood flow can be improved, motor behavior disorder is relieved, and learning cognitive ability is improved; behavioral abnormality and cerebrovascular spasm induced by subarachnoid hemorrhage can be relieved; discovered by researches on tissue distribution of the drugs, MN-08 can be gathered in pulmonary tissue, in a pulmonary arterial hypertension model, pulmonary blood vessels can be dilated, right ventricular pressure can be lowered, and plumpness of right ventricle can be reduced.
Owner:GUANGZHOU MAGPIE PHARMA

Occlusion device used for alleviating pulmonary arterial hypertension of congenital heart disease

PendingCN110226950ARelieve stressRelieve pulmonary hypertensionSurgeryPulmonary primary hypertensionReticular formation
The invention discloses an occlusion device used for alleviating the pulmonary arterial hypertension of congenital heart disease, and particularly relates to the technical field of medical apparatus and instruments. The occlusion device used for alleviating the pulmonary arterial hypertension comprises an occlusion part and a shunting part, wherein the shunting part is embedded in the axial centerposition of the occlusion part and penetrates through the occlusion part; the main body of the occlusion part is of a reticulate structure, and the periphery of the occlusion part is coated with a layer of high molecular elastic film; and a one-way valve capable of achieving one-way conduction is installed in the axial direction of the shunting part. After the occlusion device is installed, a one-way channel which prevents left-to-right shunting and only permits right-to-left shunting is formed so as to facilitating eliminating of the volume overload of pulmonary vessels and pressure conduction, further injury of pulmonary vessels is lightened, and meanwhile, right-to-left shunting is kept to prevent a serious consequence since pulmonary arterial pressure suddenly rises. The occlusion device is favorable for alleviating the pulmonary arterial hypertension of the congenital heart disease and is suitable to be prompted and used in medical organizations.
Owner:YANAN HOSPITAL OF KUNMING CITY +1

Lung tissue dissimilation degree judgment method and device

The invention provides a lung tissue dissimilation degree judgment method and device, and the method comprises the following steps: carrying out the pulmonary parenchyma segmentation of all lung CT images, and generating a pulmonary parenchyma segmentation image; performing binarization processing on the pulmonary parenchyma segmentation image to generate a pulmonary parenchyma mask image; carrying out feature enhancement processing on pulmonary vessels in all pulmonary parenchyma segmentation images to generate pulmonary vessel feature enhancement images; carrying out binarization processingon the pulmonary vessel feature enhancement image to generate a pulmonary vessel mask image; counting the number L of pulmonary parenchyma region pixel points in all pulmonary parenchyma mask images to serve as volume parameters of the pulmonary parenchyma region pixel points; counting the number V of pulmonary vessel region pixel points in all the pulmonary vessel mask images as volume parametersof the pulmonary vessel region pixel points; and based on the number L of the pulmonary parenchyma region pixel points in all the pulmonary parenchyma mask images and the number V of the pulmonary vessel region pixel points in all the pulmonary vessel mask images, calculating to obtain a pulmonary effective ventilation function region proportion ELVAR value, and outputting the ELVAR value. The method and the device provided by the invention provide a reliable basis for clinical related lung condition evaluation.
Owner:NAT UNIV OF DEFENSE TECH

Use of pinocerine in the preparation of prevention and/or treatment of pulmonary arterial hypertension

The invention relates to new pharmacological effects of a compound pinocembrin and an application of pinocembrin to preparation of products for preventing, relieving and / or treating pulmonary hypertension and complications thereof. Pinocembrin has the beneficial effects that pinocembrin has the pharmacological effects of relaxing pulmonary arteries, reducing the pulmonary artery pressure, protecting pulmonary vessels from injuries caused by pulmonary hypertension, restoring lung tissue functions, repairing heart and liver injuries, alleviating right ventricular hypertrophy and enlargement, improving heart failure and liver functions, obviously reducing the mortality of animals with pulmonary hypertension and preventing and treating pulmonary hypertension and complications thereof; pinocembrin is an active monomer separated from a natural product propolis, achieves complete synthesis at present, has good application and development prospects, is an ideal compound for treating pulmonary hypertension and complications thereof and can be applied to preparation of the products for preventing, relieving and / or treating pulmonary hypertension and complications thereof, such as chronic obstructive emphysema, chronic pulmonary heart diseases, right heart failure and liver function injuries.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI

Plugging device for unclosed hole of patent ductus arteriosus

InactiveCN104042258AControl releaseRestricted diversionOcculdersProsthesisEngineeringAortic flow
The invention discloses a plugging device for an unclosed hole of a patent ductus arteriosus. The perforated plugging device for the unclosed hole of the patent ductus arteriosus comprises a front disk for plugging a gap, a cylindrical barrier part for blocking an unclosed ductus, and a through hole penetrating through the front disk and the cylindrical barrier part; one end of the cylindrical barrier part is connected with the front disk; the other end of the cylindrical barrier part is a closed end; the diameter of the front disk is greater than that of the cylindrical barrier part; the front disk, the cylindrical barrier part and the through hole are all formed by weaving a plurality of memory alloy wires; the memory alloy wires penetrate through the through hole to form the hole wall of the through hole and are wound to form the front disk and the cylindrical barrier part; the two ends of the memory alloy wires are fixed to the same fixing clamp for restricting the memory alloy wires; the memory alloy wires are interwoven to form an elastic mesh; a sealing film is arranged in the elastic mesh. According to the perforated plugging device for the patent ductus arteriosus, the shunt of aorta-pulmonary artery is limited, and the blood flow of the aorta of a high-pressure chamber is also prevented from flowing to the pulmonary artery; the volume overload and the pressure transfer of pulmonary vessels are lightened; serious consequences caused by sudden rise of the pulmonary artery pressure can also be prevented, so that the high pressure of a right heart system has release space.
Owner:尚小珂

Application of polydatin in preparation of medicine for treating pulmonary arterial hypertension

The invention belongs to the technical field of biological medicines, and discloses application of polydatin in preparation of a medicine for treating pulmonary arterial hypertension, and application of the polydatin in preparation of a medicine for inhibiting pulmonary vascular remodeling and right heart hypertrophy to treat pulmonary arterial hypertension. The pulmonary arterial hypertension in the invention is represented by right heart hypertrophy and pulmonary vascular remodeling. The dosage of the polydatin disclosed by the invention is 30 mg/kg to 60 mg/kg. The invention provides pharmaceutical application of the polydatin in treating pulmonary arterial hypertension by improving right heart hypertrophy and pulmonary vascular remodeling. The polydatin has a remarkable inhibiting effect on pulmonary vascular remodeling and right heart hypertrophy, and can remarkably reduce the thickness of a pulmonary artery vascular wall, relieve muscle type thickening of a blood vessel middle layer and enlarge the diameter of a vascular cavity, so that the pulmonary artery pressure is reduced; the weight of the right ventricle can be obviously reduced; the right heart hypertrophy index is obviously reduced; and it is prompted that the polydatin has large potential and distant view in excavating and developing of preparation of the targeted medicine for treating pulmonary vascular remodeling.
Owner:重庆市急救医疗中心

Controllable up-regulation of ang-(1-7) expression vector for targeted prevention and treatment of hypoxic pulmonary hypertension

ActiveCN110714028BInhibition of contractionPlay a role in the prevention and treatment of hypoxic pulmonary hypertensionPeptide/protein ingredientsAntibody mimetics/scaffoldsSmooth muscleVascular endothelium
The invention discloses an expression vector for controllably up-regulating Ang-(1-7) targeted prevention and treatment of hypoxic pulmonary hypertension. The present invention constructs an HRE-enhanced, Tie2 promoter-driven Ang-(1-7) expression vector, which is specifically located in vascular endothelial cells through the Tie2 promoter, and at the same time, uses HIF-1α to express specificity only in hypoxic pulmonary vascular endothelial cells. Sexually activates HRE, thereby upregulating Ang‑(1‑7) expression. The present invention finds that the constructed expression vector is not only targeted, but also can controllably and effectively up-regulate the expression of Ang-(1-7) in hypoxic pulmonary microvascular endothelial cells according to the degree of hypoxia, and then regulate pulmonary artery smooth muscle cells , to achieve controllable hypoxia, targeted inhibition of pulmonary artery contraction and reversal of pulmonary artery structural reconstruction, and provide effective means and strategies for the prevention and treatment of hypoxic pulmonary hypertension and other diseases.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products